ClearPoint Neuro WKN: A2PZ3E ISIN: US18507C1036 Kürzel: CLPT Forum: Aktien Thema: Hauptdiskussion

https://www.streetinsider.com/dr/news.php?id=18008226 Analyst Actions: B. Riley Raises ClearPoint Neuro's Price Target to $38 From $23, Keeps Buy Rating

ClearPoint Neuro, Inc. Announces License and Research Agreement with Philips https://www.globenewswire.com/news-release/2021/02/18/2178484/0/en/ClearPoint-Neuro-Inc-Announces-License-and-Research-Agreement-with-Philips.html Collaboration will Enable ClearPoint to Develop and Launch the ClearPoint ‘Maestro Brain Model by 2022 ... Announces Pricing of Public Offering of 1,850,140 Shares of Common Stock https://www.globenewswire.com/news-release/2021/02/19/2178608/0/en/ClearPoint-Neuro-Announces-Pricing-of-Public-Offering-of-1-850-140-Shares-of-Common-Stock.html ...announced today the pricing of its underwritten public offering of 1,850,140 shares of its common stock at a price to the public of $23.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 277,520 shares of its common stock at the public offering price less underwriting discounts and commissions. All the shares are being offered by the Company. The offering is expected to close on February 23, 2021, subject to customary closing conditions. The Company intends to use the net proceeds from this offering to fund product development and research and development activities and the remainder for working capital and general corporate purposes.    ...

Absolut nachvollziehbar 😉

Man soll sich ja nicht in eine Aktie verlieben, aber hier wird’s schwierig...:D

ClearPoint Neuro, Inc. Announces Multi-Product Joint Development & Option Agreement with Blackrock Microsystems https://www.globenewswire.com/news-release/2021/02/11/2174542/0/en/ClearPoint-Neuro-Inc-Announces-Multi-Product-Joint-Development-Option-Agreement-with-Blackrock-Microsystems.html Partnership Enables ClearPoint Neuro to Compete in New and Complementary Markets ...

Ich denke, dass einiges möglich ist, aber mag nicht spekulieren über Kurse.

Würde gerne noch einmal auf meine unten stehende Frage zurückkommen. Aktuell steht die Aktie bei knapp 400 Mio USD Marktkapitalisierung. Wenn ich mir die Pipeline und die Marktgröße (jetzt auch noch Europa) ansehe, sollten Kurse über 100 USD doch möglich sein, oder? Was ist euer Gefühl?

ClearPoint Neuro files $120M mixed securities shelf https://www.streetinsider.com/dr/news.php?id=17853466&gfv=1

Die Zulassung bei Boston Scientific hat hier heute einen schönen Schub verliehen: https://stocktwits.com/jlivermore1929/message/276204186

.

Sind hier Kurse von über 100$ denkbarß die Pipeline ist ja riesig...

🍀

ClearPoint Neuro, Inc. Announces First Procedure Utilizing ClearPoint 2.0 Software in Europe https://www.globenewswire.com/news-release/2021/01/14/2159032/0/en/ClearPoint-Neuro-Inc-Announces-First-Procedure-Utilizing-ClearPoint-2-0-Software-in-Europe.html ...today reported the first utilization in Europe of its Version 2.0 software, together with the ClearPoint Neuro Navigation System, at Rigshospitalet in Copenhagen, Denmark. The procedure, which took place last week, also represents the first European site to use the ClearPoint System under live MRI guidance for navigation of a laser catheter in the brain. ...

Auf jeden Fall sollte sie hier bisher weniger bekannt sein. Für mich ein Wert, den ich definitiv nicht missen mag.

Geheimtipp?

ClearPoint Neuro, Inc. Reports Record Revenue in Preliminary Fourth Quarter 2020 Results https://www.globenewswire.com/news-release/2021/01/12/2157484/0/en/ClearPoint-Neuro-Inc-Reports-Record-Revenue-in-Preliminary-Fourth-Quarter-2020-Results.html ... Preliminary 2020 Results: Preliminary unaudited revenue for the fourth quarter of 2020 will be approximately $3.7 million, an increase of 14% over the same period in 2019. Preliminary revenue for the full-year 2020 will be an estimated $12.8 million, representing 14% growth from 2019. The Company supported 175 cases in the fourth quarter of 2020 against the backdrop of continued postponements of elective procedures due to the COVID-19 pandemic. Cash used in operations for the quarter and year ended December 31, 2020, is expected to be approximately $2.4 million and $7.9 million, respectively. The full-year amount includes the payment of $1.0 million in accumulated interest on secured indebtedness that the Company repaid in January 2020. The Company had approximately $20.1 million in cash and cash equivalents at December 31, 2020.   ...